Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-10

Study Completion Date

2025-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Septic Shock-induced Immunosuppression

NCT04067674

Septic Shock

RECRUITING

Comparison Between the Progostic Value of the Procalcitonin and the Platelet/Total Leukocytic Count Ratio in Sepsis

NCT06991686

All Conditions Causing Sepsis Pneumonia - Bacterial Urinary Tract Infection Bacterial

COMPLETED

Effects of Enteral Nutrition Content on Disease Progression in Sepsis Patients

NCT06943326

Sepsis Nutritional Deficiency

RECRUITING

Shock Indices Use for Early Mortality From Septic Shock

NCT05088109

Septic Shock Morality

UNKNOWN

Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections

NCT00934011

Severe Sepsis Septic Shock

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10.

Treatment plan will be initiated to all patients according to the burn ICU protocol.

According to the lab results, interleukin 6 and procalcitonin will guide the investigators to take decisions regarding clinical improvement and ICU stay.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Burns Sepsis Septic Shock Death

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Burn ICU patients

Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10. Treatment plan will be initiated to all patients according to the burn ICU protocol.

Group Type EXPERIMENTAL

Interleukin 6

Intervention Type DIAGNOSTIC_TEST

Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interleukin 6

Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Procalcitonin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.
* patients with burn percentage of 25% to 50% of total body surface area
* patients with second to third degree burns
* ASA 1 and ASA 2 patients